Key facts
| Recalling firm | ONESOURCE SPECIALTY PHARMA LIMITED |
|---|---|
| Manufacturer | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. |
| Brand name | METHOHEXITAL SODIUM |
| Product description | Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, Manufactured by: OneSource Specialty, Pharma Limited, Bengaluru - 561 203, India, Manufactured for: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31 |
| Classification | Class II |
| Recall number | D-0662-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Failed Impurities/Degradation Specifications |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, Manufactured by: OneSource Specialty, Pharma Limited, Bengaluru - 561 203, India, Manufactured for: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from ONESOURCE SPECIALTY PHARMA LIMITED. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from ONESOURCE SPECIALTY PHARMA LIMITED should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to ONESOURCE SPECIALTY PHARMA LIMITED directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
ONESOURCE SPECIALTY PHARMA LIMITED’s FDA history
Argus HQ has recorded 1 total FDA action tied to ONESOURCE SPECIALTY PHARMA LIMITED: 0 warning letters, 1 recall, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- What is the recall class for ONESOURCE SPECIALTY PHARMA LIMITED's recall?
- FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- Why was Methohexital Sodium for Injection, USP 500 mg Multiple Dose recalled?
- FDA's recall record states the reason as: Failed Impurities/Degradation Specifications
- Who should I contact about this recall?
- Contact ONESOURCE SPECIALTY PHARMA LIMITED directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
- Has ONESOURCE SPECIALTY PHARMA LIMITED had other FDA recalls or enforcement actions?
- This is the only FDA action Argus HQ has on file for ONESOURCE SPECIALTY PHARMA LIMITED so far. Argus ingests new FDA enforcement records daily.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for ONESOURCE SPECIALTY PHARMA LIMITEDCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Class II Recall: METHOHEXITAL SODIUM by ONESOURCE SPECIALTY PHARMA LIMITED. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/onesource-specialty-pharma-limited-d-0662-2026-2026-07-15
"FDA Class II Recall: METHOHEXITAL SODIUM by ONESOURCE SPECIALTY PHARMA LIMITED." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/onesource-specialty-pharma-limited-d-0662-2026-2026-07-15.
Argus HQ Research. "FDA Class II Recall: METHOHEXITAL SODIUM by ONESOURCE SPECIALTY PHARMA LIMITED." Digital Empire Holdings LLC. Accessed July 24, 2026. https://argushq.ai/recall/onesource-specialty-pharma-limited-d-0662-2026-2026-07-15.
@misc{argushq_argushq_ai_recall_onesource_specialty_pharma_limited_d_0662_2026_2026_07_15_2026,
title = {FDA Class II Recall: METHOHEXITAL SODIUM by ONESOURCE SPECIALTY PHARMA LIMITED},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/onesource-specialty-pharma-limited-d-0662-2026-2026-07-15},
note = {Accessed: July 24, 2026}
}Source: FDA.gov — Recalls ↗

